Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Scios is launching a comprehensive recommended use initiative for Natrecor, its acutely decompensated heart failure treatment.
Subscribe to our email newsletter
The intent of the initiative is to educate healthcare providers regarding those patients who should receive Natrecor and those for whom Scios does not recommend the use of Natrecor based on currently available clinical data.
The recommended use initiative is a response to recommendations the company recently sought from a panel of leading US cardiologists.
“We are committed to our recommended use initiative and we are confident that it will further assist healthcare professionals in identifying appropriate patients for treatment with Natrecor,” said Dr Darlene Horton, senior vice president of clinical research and medical affairs at Scios. “Natrecor continues to be an important therapy for patients presenting to the hospital with ADHF. These patients have few well-studied treatment options.”
The company says that it has disseminated a letter to more than 160,000 healthcare professionals describing those patients for whom Natrecor therapy is appropriate, as well as training its sales staff and external speakers.